

Publications: 10/1/17 – 9/30/18

1. Christopoulos KA, Cunningham WE, **Beckwith CG**, Kuo I, Golin CE, Knight K, Flynn PM, Spaulding AC, Coffin LS, Kruszka B, Kurth A, Young JD, Mannheimer S, Crane HM, Kahana SY. *AIDS and Behavior*. 2017. doi:10.1007/s10461-017-1804-8.
2. Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, **Beckwith CG**, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. *Substance Abuse Treatment, Prevention, and Policy*. 2017. May 16;12(1):24. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433052>
3. Brinkley-Rubinstein L, Rosen DL, Christopher P, Bazerman L, **Beckwith CG**. Long-acting injectable anti-retroviral therapy: An opportunity to improve HIV treatment and reduce HIV transmission among persons being released from prison facilities. *Clinical Infectious Diseases* 2017 Volume 65, Issue 7, 1 October 2017, Pages 1247–1248.
4. Dong KR, Must A, Tang AM, **Beckwith CG**, Stopka TJ. Competing priorities that rival health in adults on probation in Rhode Island: substance use recovery, employment, housing, and food intake. *BMC Public Health* (2018) 18: 289. <https://doi.org/10.1186/s12889-018-5201-7>.
5. Yellin H, **Beckwith CG**, Kurth A, Liu T, Castonguay B, Patrick R, Trezza C, Bazerman L, Kuo I. Syndemic effect of mental illness and substance use on viral suppression among recently-incarcerated, HIV-infected individuals in the CARE+ Corrections study. *AIDS Care*. 2018. Apr 1: 1-5. PMID:29607658. DOI: [10.1080/09540121.2018.1455961](https://doi.org/10.1080/09540121.2018.1455961)
6. **Beckwith CG**, Kuo I, Fredericksen RJ, Brinkley-Rubinstein L, Cunningham WE, Springer SA, et al. (2018) Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative. *PLoS ONE* 13 (5): e0197730. <https://doi.org/10.1371/journal.pone.0197730>
7. Dong KR, Tang AM, Stopka TJ, **Beckwith CG**, Must A (2018) Food acquisition methods and correlates of food insecurity in adults on probation in Rhode Island. *PLoS ONE* 13(6): e0198598. <https://doi.org/10.1371/journal.pone.0198598>.
8. Dong KR, Must A, Tang AM, Stopka TJ, **Beckwith CG**. Food insecurity, morbidities, and substance use in adults on probation in Rhode Island. *Journal of Urban Health*. 2018. Published online 20 July 2018. <https://doi.org/10.1007/s11524-018-0290-2>.

Publications: 10/1/17 – 9/30/18

9. Kaul KL, Sabatini LM, Tsongalis GJ, **Caliendo AM**, Olsen RJ, Ashwood AR, Bale S, Benirschke B, Carlow D, Funke BH, Grody WW, Hayden RT, Hegde M, Lyon E, Murata K, Pessin M, Press RD, Thomson RB. The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care. *Academic Pathology* 2017;4:1-21.
10. Lorenz ML, Bouton TC and **Caliendo AM**. First reported case of vertebral osteomyelitis due to *Erysipelothrix rhusiopathiae*. *IDCases* 2017; Nov 10;11:3-5. doi: 10.1016/j.idcr.2017.11.002. eCollection 2018.
11. Clancy CJ, Pappas PG, Vazquez J, Judson MA, Kontoyiannis DP, Thompson GR, Garey KW, Reboli A, Greenberg RN, Apewokin S, Lyon GM, Ostrosky-Zeichner L, Wu AHB, Tobin E, Nguyen MH and **Caliendo AM**. Detecting infections rapidly and easily for Candidemia Trial-Part 2 (DIRECT2): A prospective, multicenter study of the T2Candida panel. *Clin Infect Diseases*. 2018 Feb 9. doi: 10.1093/cid/cix1095.
12. Sam SS, **Caliendo AM**, Ingersoll J, Abdul-Ali D, Kraft CS. Performance evaluation of the Aptima HSV-1 and 2 assay for the detection of HSV in cutaneous and mucocutaneous lesions. *J Clin Virology*. 2018 Feb - Mar;99-100:1-4. doi: 10.1016/j.jcv.2017.12.006. Epub 2017 Dec 13.
13. Sam SS, Ingersoll J, Racsa LD, **Caliendo AM**, Racsa PN, Igwe D, Abdul-Ali D, Josephson C, Kraft CS. Long-term stability of CMV DNA in human breast milk. *J Clin Virology*, 2018 May;102:39-41. doi: 10.1016/j.jcv.2018.02.014. Epub 2018 Feb 21.
14. Kotton CN, Kumar D, **Caliendo AM**, Huprikar S, Chou S, Danziger-Isakov L, and Humar<sup>7</sup> A on behalf of The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid organ transplantation. *Transplantation*. 2018 Mar 29. doi: 10.1097/TP.0000000000002191
15. Sam SS, **Caliendo AM**, Ingersoll J, Abdul-Ali D, Hill C, Kraft CS. Evaluation of Performance Characteristics of Panther Fusion Assays for the Detection of Respiratory Viruses from Nasopharyngeal and Lower Respiratory Tract Specimens. *J Clin Micro*, 2018. In Press.
16. Cabral DJ, Wurster JI, Flokas ME, Alevizakos M, Zabat M, Korry BJ, Rowan AD, Sano WH, Andreatos N, Ducharme RB, **Chan PA**, **Mylonakis E**, **Fuchs BB**, Belenky P. The salivary microbiome is consistent between subjects and resistant to impacts of short-term hospitalization. *Sci Rep* 2017;7(1):11040. doi: 10.1038/s41598-017-11427-2. PMID: 28887570
17. Li XC, Kusi L, Marak T, Bertrand T, **Chan PA**, Galárraga O. “The Cost and Cost-utility of Three Public Health HIV Case-finding Strategies: Evidence from Rhode Island, 2012-2014.” *AIDS Behav*. 2017 Oct 27.

Publications: 10/1/17 – 9/30/18

18. Wray TB, **Chan PA**, Celio MA, Pérez AE, Adia AC, Simpanen EM, Woods LA, Monti PM. “HIV Testing Among Men Who Have Sex with Men in the Northeastern United States.” *AIDS Behav.* 2017 Nov 8.
19. Patel RR, Presti R, Harrison LC, Powderly WG, **Chan PA**. “Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.” *Antivir Ther.* 2017 Nov 23.
20. Magaziner S, Montgomery MC, Bertrand T, Daltry D, Jenkins H, Kendall B, Molotnikov L, Pierce L, Smith E, Sosa L, van den Berg JJ, Marak T, Operario D, **Chan PA**. “Public health opportunities and challenges in the provision of partner notification services: the New England experience.” *BMC Health Serv Res.* 2018 Jan 31;18(1):75.
21. Mayer KH, **Chan PA**, Patel R, Flash CA, Douglas S Krakower. “Evolving models and ongoing challenges for HIV pre-exposure prophylaxis implementation in the United States.” *J Acquir Immune Defic Syndr.* 2018 Feb 1.
22. Brinkley-Rubinstein L, Dauria E, Tolou-Shams M, Christopoulos K, **Chan PA**, **Beckwith CG**, Parker S, Meyer J. The path to implementation of HIV pre-exposure prophylaxis for people involved in criminal justice systems. *Current HIV/AIDS Reports* 2018. Published online 08 March 2018. <https://doi.org/10.1007/s11904-018-0389-9>.
23. **P Chan**, MC Montgomery, J Rose, A Tributino, C Crowley, MM Medina, R Patel, K Mayer, **R Kantor**, AS Nunn. Statewide Evaluation of New HIV Diagnoses in Rhode Island: Implications for Prevention. *Public Health Rep.* 2018 [Epub ahead of print].
24. **Cunha CB**, Cunha BA. Rash and Fever. In: Vincent JL, Abraham E, Moore FA, Kochanek PM, Fink MP (eds.): *Textbook of Critical Care*, (7<sup>th</sup> Edition). Elsevier, New York, 2017
25. Cunha BA, **Cunha CB**: Vancomycin Ineffective in Eliminating MRSA Colonization of Respiratory Secretions in Ventilated ICU Patients: A Clinical and Pharmacokinetic Perspective. *Clinical Infectious Diseases* 66:981-982, 2018
26. Cunha BA, Baron J, **Cunha CB**: Minocycline: Clinical, Pharmacokinetic, and ASP Considerations. *Expert Review of Anti-infective Therapy* (in press), 2018
27. Parente DM, **Cunha CB**, **Mylonakis EM**, Timbrook, TT: The Clinical Utility of Methicillin Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A diagnostic Meta-analysis with Antimicrobial Stewardship Implications. *Clinical Infectious Diseases* 67: (in press), 2018
28. Cunha BA, Baron J, **Cunha CB**: Monotherapy with High-Dose Once-Daily Tigecycline is Highly Effective Against *Acinetobacter baumannii* and other Multidrug-Resistant (MDR) Gram-Negative Bacilli (GNB). *International Journal of Antimicrobial Agents* (in press), 2018

29. Vigliani MB, **Cunha CB**: Multiple Recurrent Abscesses due to *B. gladioli* in an Adult with IL-12 Deficiency Mimicking LGV. *ID Cases* (in press), 2018
30. **Cunha C, Opal SM**. What strategies can be used to optimize antibiotic use in the critically ill? In: Evidence-based Critical Care Medicine C. Deutschmann (editor). Elsevier Publishers. Edition 3, Philadelphia, PA 2018 (in press).
31. **Cunha C, Opal SM**. Antibiotic stewardship strategies to minimize antibiotic resistance while maximizing antibiotic effectiveness. In: Medical Clinics of North America (editors). Elsevier Publishers. Edition 3, Philadelphia, PA 2018 (in press).
32. Stringer EM, Kendall MA, Lockman S, Campbell TB, Nielsen-Saines K, Sawe F, **Cu-Uvin S**, Wu X, Currier JS. Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy. *PLoS One*. 2018 Jul 18;13(7):e0199555. doi: 10.1371/journal.pone.0199555. eCollection 2018.
33. Saravanan S, Gomathi S, Delong A, Kausalya B, Sivamalar S, Poongulali S, Brooks K, Kumarasamy N, Balakrishnan P, Solomon SS, **Cu-Uvin S, Kantor R**. High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy. *J Antimicrob Chemother*. 2018 Aug 1;73(8):2152-2161. doi: 10.1093/jac/dky154. PMID: 29800305
34. Kojic EM, Conley L, Bush T, **Cu-Uvin S**, Unger ER, Henry K, Hammer J, Escota G, Darragh TM, Palefsky JM, Brooks JT, Patel P. Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study. *J Infect Dis*. 2018 Apr 23;217(10):1544-1552. doi: 10.1093/infdis/jiy087. PMID: 29452366
35. Adam GP, Di M, **Cu-Uvin S**, Halladay C, Smith BT, Iyer S, Trikalinos TA. Strategies for improving the lives of US women aged 40 and above living with HIV/AIDS: an evidence map. *Syst Rev*. 2018 Feb 2;7(1):25. doi: 10.1186/s13643-018-0684-y. PMID: 29391059
36. Araos R, Montgomery V, Ugalde JA, Snyder GM, **D'Agata EMC**. Microbial disruption indices to detect colonization with multidrug-resistant organisms. *Infection Control and Hospital Epidemiology* 2017;38:1312-8.
37. **D'Agata EMC**. Addressing the Problem of Multidrug-Resistant Organisms in Dialysis [perspectives]. *Clin J Amer Soc Nephrol* 2018 (in press)
38. **D'Agata EMC**. *Pseudomonas* species, including *Pseudomonas aeruginosa*” In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (9<sup>th</sup> edition) 2018
39. Stone JA, Knoll B, **Farmakiotis D**. Relapsing EBV encephalitis in a renal transplant recipient. *IDCases* 2017; 10: 83-7. PMID: 29021960.

40. Weiss Z, Mehta M, Aung SN, Migliori M, **Farmakiotis D**. Rapid reversal of complete binocular blindness with high-dose corticosteroids and lumbar drain in a solid organ transplant recipient with cryptococcal meningitis and immune reconstitution syndrome: first case study and literature review. *Open Forum Infect Dis* 2018; 5(2): ofy007. PMID: 29423423.
41. Lin S, Chen R, Zhu S, Wang H, Wang L, Zou J, Yan J, Zhang X, **Farmakiotis D**, Tan X, **Mylonakis E**. Candidemia in adults at a tertiary hospital in China: Clinical characteristics, species distribution, resistance and outcomes. *Mycopathologia* 2018; in press. PMID: 29572768.
42. Fung M, Jacobsen E, Freedman A, Prestes D, **Farmakiotis D**, Gu X, Nguyen P, Koo S. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. *Clin Infect Dis* 2018; in press. PMID: 29800121.
43. Serpa JA, Knights S, **Farmakiotis D**, Campbell J. Brucellosis in adults and children: A ten-year retrospective review in Houston, Texas. *South Med J* 2018;111(6):324-7. PMID: 29863218.
44. Le A, **Farmakiotis D**, Reagan JL. Pruritic rash in a patient with Hodgkin's lymphoma [bleomycin-induced flagellate dermatosis]. *Cureus* 2018; 10(4): e2450. PMID: 29888154.
45. Kiriazova T, Postnov O, Bingham T, Myers J, **Flanigan T**, Vitek C, Neduzhko O. Patient and provider perspectives inform an intervention to improve linkage to care for HIV patients in Ukraine. (2018) *BMC Health Serv Res*. Jan 30; 18(1):58. doi: 10.1186/s12913-018-2885-4. PMID: 29378581
46. Patel K, Johnson J, Zacharioudakis I, Boxerman J, **Flanigan T**, **Reece R**. First confirmed case of Powassan neuroinvasive disease in Rhode Island. (2018) *ID Cases*. Mar 23; 12: 84-7. Doi: 10.1016/j.idcr.2018.03.016. PMID: 29942757. PMCID: PMC6010959
47. McCarthy M, **Flanigan T**, **Johnson J**, **Reece R**. Prescribing doxycycline for a Lyme patient you have never met: uncharted territory. (2018) *Infect Dis Clin Pract*. May;26(3): e10.
48. Freedberg KA, Kumarasamy N, Borre ED, Ross EL, Mayer KH, Losina E, Swaminathan S, **Flanigan TP**, Walensky RP. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India. (2018) *AIDS Res Hum Retroviruses*. May 3. doi: 10.1089/ AID.2017.0258. PMID 29620932
49. Li DD, **Fuchs BB**, Wang Y, Huang XW, Hu DD, Sun Y, Chai D, Jiang YY, **Mylonakis E**. Histone acetyltransferase encoded by NGG1 is required for morphological conversion and virulence of *Candida albicans*. *Future Microbiology*. 2017: 12:1497-1510.

50. Zheng Z, Liu Q, Kim W, Tharmalingam N, **Fuchs BB, Mylonakis E**. Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of *Staphylococcus aureus*. *Future Med Chem*. 2018;10(3):283-296.
51. Rossoni RD, de Barros PP, de Alvarenga JA, Ribeiro FC, Velloso MDS, **Fuchs BB, Mylonakis E**, Jorge AOC, Junqueira JC. Antifungal activity of clinical *Lactobacillus* strains against *Candida albicans* biofilms: identification of potential probiotic candidates to prevent oral candidiasis. *Biofouling*. 2018;34(2):212-225.
52. Kim W, Hendricks GL, Tori K, **Fuchs BB, Mylonakis E**. Strategies against methicillin-resistant *Staphylococcus aureus* persisters. *Future Med Chem*. 2018;10(7):779-794.
53. de Barros PP, Scorzoni L, Ribeiro FC, Fugisaki LRO, **Fuchs BB, Mylonakis E**, Jorge AOC, Junqueira JC, Rossoni RD. *Lactobacillus paracasei* 28.4 reduces in vitro hyphae formation of *Candida albicans* and prevents the filamentation in an experimental model of *Caenorhabditis elegans*. *Microb Pathog*. 2018;117:80-87.
54. Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, Fricke N, Conery AL, Shen S, Pan W, Lee K, Rajamuthiah R, **Fuchs BB**, Vlahovska PM, Wuest WM, Gilmore MS, Gao H, Ausubel FM, **Mylonakis E**. A new class of synthetic retinoid antibiotics effective against bacterial persisters. *Nature*. 2018;556(7699):103-107.
55. Sá NP, Paula LFJ, Lopes LFF, Cruz LIB, Matos TTS, Lino CI, Oliveira RB, Souza-Fagundes EM, **Fuchs BB, Mylonakis E**, Johann S. In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and resistant isolates of *Candida albicans*. *J Glob Antimicrob Resist*. 2018; pii: S2213-7165(18)30079-1.
56. Tharmalingam N, Rajmuthiah R, Kim W, **Fuchs BB**, Jeyamani E, Kelso MJ, **Mylonakis E**. Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant *Staphylococcus aureus*-*Caenorhabditis elegans* High-Throughput Screen. *Microb Drug Resist*. 2018;24(5):666-674.
57. Porrassa AMG, Terra B, Bragaa TC, Magalhã TFF, Martins CVB, da Silva DL, Ferreira Gouveia LMB, de Freitasb GSJ, Santosb DA, Resende-Stoianof MA, **Fuchs BB, Mylonakis E**, de Freitas RP, de Fátima A. Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities *J Adv Res*. 2018 Jun 21;14:81-91. doi: 10.1016/j.jare.2018.06.004. eCollection 2018 Nov. PMID: 30009053
58. de Sá NP, de Lima CM, dos Santos JR, da Costa MC, de Barros PP, Junqueira JC, Vaz JA, de Oliveira RB, **Fuchs BB, Mylonakis E**, Rosa CA, Santos DA, Johann S. A phenylthiazole derivative demonstrates efficacy on treatment of the cryptococcosis and candidiasis in animal models. *Future Sci OA*. *Future Sci OA*. 2018 Apr 25;4(6):FSO305. doi: 10.4155/fsoa-2018-0001. eCollection 2018 Jul. PMID: 30057783

Publications: 10/1/17 – 9/30/18

59. Liu Q, Zheng Z, Kim W, **Fuchs BB**, **Mylonakis E**. Influence of sub-inhibitory concentrations of NH125 on biofilm formation and virulence factors of *Staphylococcus aureus*. *Future Med Chem*. 2018 Jun 1;10(11):1319-1331. doi: 10.4155/fmc-2017-0286. Epub 2018 May 30. PMID: 29846088
60. Wang Y, Bia S, Wang TT, **Fuchs BB**, Hua DD, Anastassopoulou CG, Desalermos A, Muhammed M, Wu CL, Jiang YY, **Mylonakis E**. *SDH2* is involved in proper hypha formation and virulence in *Candida albicans*. *Future Microbiol* (in press).
61. **Fuchs BB**, Tharmalingam N, **Mylonakis E**. Vulnerability of long-term care facility residents to *Clostridium difficile* infection due to microbiome disruptions. *Future Microbiol* (in press)
62. Carter K, Gabrellas A, Shah S, **Garland JM**. “Improved Latent Tuberculosis Therapy Completion Rates in Refugee Patients Through Use of a Clinical Pharmacist.” *Int J Tuberculosis and Lung Disease*: 2017. 21(4):432-437. doi: 10.5588/ijtld.16.0575, PMID: 28284259.
63. **Garland JM**, Levinson A, **Wing E**. Care of Critically Ill Patients with HIV: Cunha CB, Cunha BA, (Editors), *Infectious Diseases and Antimicrobial Stewardship in Critical Care Medicine* (4th Edition). CRC Press, Boca Raton, 2018, in press.
64. HA Duarte, N Panpradist, IA Beck, B Lutz, J Lai, R Kanthula, **R Kantor**, A Tripathi, S Saravanan, I MacLeod, MH Chung, G Zhang, C Yang, LM Frenkel. Current status of point-of-care testing for HIV drug resistance. *Journal of Infectious Diseases* 2017;216(suppl 9):S824-S828. PMID 29040621
65. C Godfrey, M Bobkova, C Boucher, G Ravasi, P Chen, F Zhang, Y Wu, **R Kantor**. Regional challenges in HIV drug resistance. *Journal of Infectious Diseases* 2017;216(suppl 9):S816-S819. PMID 28968824. PMC 5853282.
66. M Coetzer, L Ledingham, L Diero, E Kemboi, M Orido, **R Kantor**. *Gp41* and *Gag* amino acids linked to HIV-1 Protease Inhibitor Based 2<sup>nd</sup>-line Failure in HIV-1 subtype A from Western Kenya. *Journal of the International AIDS Society* 2017;20: 20:e25024. PMID 29098809. PMC 5810327.
67. **R Kantor**, A DeLong, L Schreier, M Reitsma, E Kemboi, M Orido, S Obonge, R Boinett, M Rono, W Emonyi, N Buziba, L Diero. Second-Line Treatment Failure, Drug Resistance and Resistance Accumulation among HIV-Infected Patients in a Large Treatment Program in Western Kenya (in press, *AIDS*).
68. van den Berg JJ, Javanbakht M, Gorbach PM, Rudy BJ, Westfall AO, Wilson CM, **Lally MA**; and The Adolescent Medicine Trials Network for HIV/AIDS Interventions. Partner Notification for Youth Living with HIV in 14 Cities in the United States. *JAIDS* 77(1)46-52, 2018. [Epub 10/4/17] PMID29023252 PMC5730071
69. **Lally MA**, van den Berg JJ, Westfall AO, Rudy B J, Hosek SG, et al; and The

Publications: 10/1/17 – 9/30/18

- Adolescent Medicine Trials Network for HIV/AIDS Interventions. HIV Continuum of Care for Youth in the United States. *JAIDS* 77(1):110-117, 2018. [Epub 10/4/17] PMID28991884 PMC5774627.
70. Baker Z, Javanbakht M, Mierzwa S, Pavel C, **Lally MA**, Zimet G, Gorback P. Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data. *AIDS and Behavior* 22(4):1174-1183, 2018. (Epub 10/27/17) PMID29079950
  71. Gamarel KE, Nichols S, Kahler CW, Westfall AO, **Lally MA**, Wilson CM and the Adolescent Medicine Trials Network for HIV/AIDS Intervention. A cross-sectional study examining associations between substance use frequency, problematic use, and sexually transmitted infections among youth living with HIV. *Sexually Transmitted Infections* 94(4):304-308, 2018. [Epub 11/27/17] PMID29180537
  72. Whiteley L, Brown L, **Lally MA**, Heck N, van den Berg JJ. A Mobile Gaming Intervention to Increase Adherence to Antiretroviral Treatment for Youth Living With HIV: Development Guided by the Information, Motivation, and Behavioral Skills Model. *JMIR Mhealth Uhealth*, 6(4):e96, 2018. PMID29685863
  73. Hauser N, Cervera-Hernandez ME, **Lonks J**, Zaidi N. Rare but not forgotten: A case of meningitis due to ceftriaxone-resistant *Streptococcus pneumoniae*. *IDCases*. 2018 Jan 31;11:73. doi: 10.1016/j.idcr.2018.01.008. eCollection 2018.
  74. Rice LB, Desbonnet C, Tait-Kamradt A, Garcia-Solache M, **Lonks J**, Moon TM, D'Andréa ÉD, Page R, Peti W. Structural and Regulatory Changes in PBP4 Trigger Decreased  $\beta$ -Lactam Susceptibility in *Enterococcus faecalis*. *MBio*. 2018 Apr 3;9(2). pii: e00361-18. doi: 10.1128/mBio.00361-18.
  75. **Lonks J**. Infection control and antimicrobial stewardship. *RI Med J* 2018 Jun1;101(5):35-37.
  76. **Mermel LA**. Short-term peripheral venous catheter-related bloodstream infections: a systematic review. *Clin Infect Dis* 65:1757–1762, 2017.
  77. Harris D, Cooper E, Vanner C, **Mermel LA**. Respiratory viral testing in laboratories serving acute care hospitals in Rhode Island. *Med Health RI* 100:29-30, 2017.
  78. Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K, Easom AM, Mokrzycki MH, Newcomb B, Patel PR, **Mermel LA**, Chand D. Recommended clinical trial endpoints for catheters. *Clin J Am Soc Nephrol* 13:495-500, 2018.
  79. Baskin KM, Abu-Elmagd K, Doellman D, Drews BB, Durack JC, Journeycake JM, Kocoshis SA, McLennan G, Rupp SM, Towbin RB, Wasse H, **Mermel LA**, Toomay SM, Camillus JC, Ahrar K, White SB. Chronic central venous access: From research consensus panel to national multi-stakeholder initiative. *J Vasc Interv Radiol* 29:461–469, 2018.



Publications: 10/1/17 – 9/30/18

80. Chow EJ, **Mermel LA**. More than a cold: Hospital-acquired respiratory viral infections, sick leave policy and a need for culture change. *Infect Control Hosp Epidemiol* 39:861-862, 2018.
81. Jefferson J, **Mermel LA**. Coordination of infection control activities at the healthcare system level: survey results (letter). *Infect Control Hosp Epidemiol* 39:121-122, 2018.
82. **Mermel LA**. My Mentor. *Wis Med J* 116:189, 2018. \*MMWR, an official publication the Centers for Disease Control & Prevention, is extensively reviewed within the CDC prior to publication.
83. Yousaf, A, Baird GL, **Mermel LA**. Association of infectious disease consultation with clinical outcomes in patients with Staphylococcus aureus bacteremia at low risk for endocarditis. *Open Forum Infect Dis* <https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofy142/5037839>. [Epub ahead of print].
84. Timsit J-F, Rupp M, Bouza E, Chopra V, Karpanen T, Laupland K, Lisboa T, **Mermel LA**, Mimoz O, Parienti J-J, Poulakou G, Souweine B, Zingg W. A state of the art review on optimal practices to prevent, recognize, and manage complications associated with intravascular devices in the critically ill. *Intensive Care Med* 2018 May 12. doi: 10.1007/s00134-018-5212-y. [Epub ahead of print].
85. **Mermel LA**. The great influenza centennial – What have we learned about the epidemiology and prevention of transmissions? *Clin Microbiol Infect* 2018 Jul 11. pii: S1198-743X(18)30494-4. doi: 10.1016/j.cmi.2018.07.001. [Epub ahead of print].
86. Chow EJ, Smit MA, **Mermel LA**. Visitor screening and staff sick leave policies in US hospitals. *Infect Control Hosp Epidemiol* 2018 Jun 21:1-3. doi: 10.1017/ice.2018.131. [Epub ahead of print]
87. Levinson AT, Chapin KC, LeBlanc L, **Mermel LA**. Peripheral arterial catheter colonization in cardiac surgical patients. *Infect Control Hosp Epidemiol* 2018 Jun 26:1-2. doi:10.1017/ice.2018.127. [Epub ahead of print]
88. Montague BM, Salas C, Montague T, **Mileno MD**. Immunocompromised Travelers. *In: Infectious Diseases: A Geographic Guide, USA*, Wiley Blackwell, 2017: 419-45.
89. Kotton CN, **Mileno MD**. The Immunocompromised Traveler. *In: Travel Medicine Textbook*, Chapter 27, Elsevier, in press.
90. **Mileno MD, Nau GJ, Larkin J, Sanchez MC, Garland JM, Lonks JR, Lau C**. Vaccines for Travelers. *In: Vaccinations*, Poland, in press.

Publications: 10/1/17 – 9/30/18

91. Closson EF, **Mitty JA**, Malone J, Mayer KH, Mimiaga MJ. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. *AIDS Care*. 2018 Feb;30(2):191-198. doi: 10.1080/09540121.2017.1360992.
92. Andreatos N, Grigoras C, Shehadeh F, Pliakos EE, Stukides G, Port J, Flokas ME, **Mylonakis E**. The impact of HIV infection and socioeconomic factors on the incidence of gonorrhea: A county-level, US-wide analysis. *PLoS ONE* 2017;12(9):e0183938. doi: 10.1371/journal.pone.0183938. PMID: 28863154
93. Lee K, **Mylonakis E**. An intestine-derived neuropeptide controls avoidance behavior in *Caenorhabditis elegans*. *Cell Rep*. 2017;20(10):2501-2512. PMID: 28877481
94. Xiao X, Feng J, Li Y, Chen Z, Shi M, Xi L, **Mylonakis E**, Zhang J. *Agrobacterium tumefaciens*-mediated transformation: an efficient tool for targeted gene disruption in *Talaromyces marneffei*. *World J Microbiol Biotechnol*. 2017;33(10):183. doi: 10.1007/s11274-017-2352-0. PMID: 28948456
95. Flokas ME, Andreatos N, Alevizakos M, Kalbasi A, Onur P, **Mylonakis E**. Inappropriate management of asymptomatic patients with positive urine cultures: A systematic review and meta-analysis. *Open Forum Infect Dis*. 2017;20(4):ofx207. PMID: 29226170
96. Grigoras CA, Karanika S, Velmahos E, Alevizakos M, Flokas ME, Kaspiris-Rousellis C, Evaggelidis IN, Artelaris P, Siettos CI, **Mylonakis E**. Correlation of opioid mortality with prescriptions and social determinants: a cross-sectional study of Medicare enrollees. *Drugs*. 2018;78(1):111-121. PMID: 29159797
97. Tharmalingam N, Port J, Castillo D, **Mylonakis E**. Repurposing the anthelmintic drug niclosamide to combat *Helicobacter pylori*. *Sci Rep*. 2018;8(1):3701. PMID: 29487357
98. Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, **Mylonakis E**, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumour necrosis factor- $\alpha$  agents). *Clin Microbiol Infect*. 2018 Feb 6. pii: S1198-743X(18)30030-2. doi: 10.1016/j.cmi.2017.12.025. PMID: 29459143
99. **Mylonakis E**, Zacharioudakis IM, Clancy CJ, Nguyen MH, Pappas PG. The efficacy of T2 magnetic resonance assay in monitoring candidemia after the initiation of antifungal therapy: The Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) trial. *J Clin Microbiol*. 2018 Mar 26;56(4). pii: e01756-17. doi: 10.1128/JCM.01756-17. Print 2018 Apr. PMID: 29367293
100. Tansarli GS, **Mylonakis E**. ACP Journal Club. Fecal microbiota transplantation by oral capsule was noninferior to colonoscopy for recurrence of *C. difficile* infection at 12 wk

- Ann Intern Med.* 2018 Mar 20;168(6):JC31. doi: 10.7326/ACPJC-2018-168-6-031. No abstract available. PMID: 29554669
101. Zacharioudakis IM, Zervou FN, **Mylonakis E**. T2 magnetic resonance assay: Overview of available data and clinical implications. *J Fungi (Basel)*. 2018 Apr 4;4(2). pii: E45. doi: 10.3390/jof4020045. Review. PMID: 29617284
  102. Araos R, Andreatos N, Ugalde J, Mitchell S, **Mylonakis E**, D'Agata **EMC**. The fecal microbiome among nursing home residents with advanced dementia and *Clostridium difficile*. *Dig Dis Sci*. 2018 Mar 28. doi: 10.1007/s10620-018-5030-7. [Epub ahead of print] PMID: 29594967
  103. Andreatos N, Shehadeh F, Pliakos EE, **Mylonakis E**. The impact of antibiotic prescription rates on the incidence of MRSA bloodstream infections: a county-level, U.S.-wide analysis. *Int J Antimicrob Agents*. 2018 Apr 12. pii: S0924-8579(18)30105-5. doi: 10.1016/j.ijantimicag.2018.04.003. [Epub ahead of print] PMID: 29656062
  104. Huang X, Liu Y, Xi L, Zeng K, **Mylonakis E**. *Galleria mellonella* as a model invertebrate host for the study of muriform cells of dematiaceous fungi. *Future Microbiol* (in press).
  105. Pliakos E, Andreatos N, Ziakas PD, **Mylonakis E**. The cost-effectiveness of rapid diagnostic testing for the diagnosis of bloodstream infections with or without antimicrobial stewardship *Clin Microbiol Rev*. 2018 May 30;31(3). pii: e00095-17. doi: 10.1128/CMR.00095-17. Print 2018 Jul. Review. PMID: 29848775
  106. Zacharioudakis IM, Zervou FN, **Mylonakis E**. Use of T2MR in invasive candidiasis with and without candidemia. *Future Microbiol*. 2018 May 24. doi: 10.2217/fmb-2018-0079. [Epub ahead of print] PMID: 29792512
  107. Ziakas PD, Kourbeti IS, Poulou LS, Vlachogeorgos GS, **Mylonakis E**. Medicare Part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect". *PLoS One*. 2018 Jun 7;13(6):e0198674. doi: 10.1371/journal.pone.0198674. eCollection 2018. PMID: 29879194
  108. Tansarli GS, **Mylonakis E**. Efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults: A systematic review and meta-analysis. *Antimicrob Agents Chemother*. 2018 Jul 9. pii: AAC.00635-18. doi: 10.1128/AAC.00635-18. [Epub ahead of print] PMID: 29987137
  109. Johnston T, Van Tyne D, Chen RF, Fawzi NL, Kwon B, Kelso MJ, Gilmore MS, **Mylonakis E**. Propyl-5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate(HMPC): a new bacteriostatic agent against methicillin—resistant *Staphylococcus aureus*. *Sci Rep* 2018 May 4;8(1):7062. doi: 10.1038/s41598-018-25571-w. PMID: 29728636.

Publications: 10/1/17 – 9/30/18

110. Pliakos EE, Andreatos N, Ziakas PD, **Mylonakis E**. The cost-effectiveness of antimicrobial lock solutions for the prevention of central line-associated bloodstream infections. *Clin Infect Dis*. 2018 Jun 26. doi: 10.1093/cid/ciy511. [Epub ahead of print] PMID: 29945237
111. de Sá NP, Pôssa AP, Perez P, Ferreira JM, Fonseca NC, Lino CI, Cruz LB, de Oliveira RB, Rosa CA, Borelli BM, **Mylonakis E**, **Fuchs BB**, Johann S. A Antifungal activity directed toward the cell wall by 2-cyclohexylidenhydrazo-4-phenyl-thiazole against *Candida albicans*. *Infect Disord Drug Targets*. 2018 May 30. doi: 10.2174/1871526518666180531101605. [Epub ahead of print] PMID: 29852876
112. Tansarli GS, **Mylonakis E**. ACP Journal Club. Procalcitonin-guided antibiotic treatment did not reduce antibiotic use in suspected lower respiratory tract infection in the ED. *Ann Intern Med*. (in press).
113. **Neill MA**, Carpenter CCJ. Other pathogenic vibrios. In: *Principles and Practice of Infectious Disease*. 9<sup>th</sup> Edition. JE Bennett, R. Dolin, MJ Blaser, eds. Elsevier, 2018
114. Banerjee D, **Opal SM**. Sepsis, aging and exercise (editorial). *Critical Care* 2017; Nov 23; 21:286. doi: 10.1186/s 13054-017-1840-9
115. Shea BS, **Opal SM**. Editorial-S1PR3 signaling drives bactericidal killing and is required for survival in bacterial sepsis. *American Journal of Respiratory and Critical Care Medicine* 2017; 196;(12): 1500-1502.
116. Hotchkiss R, **Opal SM**, Mullard A, Cohen J. Editorial commentary. Sepsis researchers set sights on immunotherapeutic strategies. *Nature Reviews/Drug discovery*. 2018; 17:381-383.
117. Caffrey AR, Timbrook TT, Noh E, Sakoulas G, **Opal SM**, Nizet V, La Plante K. Evidence to support continuation of statin use during *Staphylococcus aureus* bacteremia. *Antimicrobial Agents and Chemotherapy* 2017; 61(3): e02228-16
118. Rello J, van Engelen T, Alp E, Calandra T, Cattoir V, Kern W, Netea M, Nseir S, **Opal SM**, van de Veerdonk FL, Wilcox M, Wiersinga J. Towards personalized medicine in sepsis: A position paper of the European Society of Clinical Microbiology and Infectious Diseases. *European Journal of Clinical Microbiology and Infection* 2018; Mar 23.S1198-&43X(18)30221-0 doi:10.1016/j.cmi.2018.03.011.
119. Lewis, RJ, Angus DC, Laterre P-F, Kjolbye AL, van der Meulen E, Blemings A, Graves T, Russell J, Carlson J, Jacoben K, Yealy DM, **Opal SM**, Windeløv NA, Francois B, Perner, Pickkers, P MD, Berry SM. Rationale and Design for an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock: SEPSIS-ACT (Selepressin Evaluation Program for Sepsis-Induced Shock - Adaptive Clinical Trial) *Annals of the American Thoracic Society*. 2018 (in press)

Publications: 10/1/17 – 9/30/18

120. Miller RR, Lopansri BK, Burke JP, Levy M, **Opal SM**, Rothman RE, D'Alessio FR, Sidhaye R, N. Aggarwal N, Balk R, Greenberg J, Yoder M, Patel G, Gilbert E, Afshar M, Parada J, Martin GS, Esper A, Kempker J, Narasimhan M, Tsegaye A, Hahn S, Mayo P, van der Poll T, et al. Validation of a Molecular Host Response Assay, Septicyte™ LAB, for Discriminating Sepsis from SIRS in Critically Ill Adults. *American Journal of Respiratory and Critical Care Medicine* 2018; Apr 6, doi:10.1164/rccm.201712-2472OC
121. Welte T, Dellinger RP, Ebert H, Torres A, Ferer S, Vincent J-L, Singer M, **Opal SM**. et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation in patients with severe community-acquired pneumonia: A multicentre, double-blind, randomized, placebo-controlled, multicenter phase II trial (CIGMA study). *Intensive Care Medicine* 2018; Apr 9: 1-11, doi.org/10.1007/s00134-018-5143-7.
122. Banerjee D, Monaghan S, Zhao R, Walsh T, Phillips G, **Opal SM**, Levy MM. Soluble PD-1 and PD-L1 in sepsis: A Preliminary Study. *Critical Care* 2018; 22:146; doi:10.1186/s13054-018-2064-3.
123. Kalil AC, **Opal SM**. Molecular targets for therapy In: Sepsis Definitions, Pathophysiology and the Challenge of Bedside Management. Nicholas S. Ward & Mitchell M. Levy editors, chapter 6. Respiratory Medicine Series. Humana Press, Springer International Press, Geneva, Switzerland, 2017 pp.89-106.
124. **Opal SM**. Urinary tract infections in the ICU. In: Intensive Care Medicine, Irwin, Cerra, Rippe (editors), Lippincott, Williams and Wilkins, Philadelphia, PA. 8th edition, 2018. Chapter 80, pp.755-764.
125. Cross AS, **Opal SM**. “Novel Targets for Drug Development.” In: Inflammation: From Molecular and Cellular Mechanisms to the Clinic. J-M Cavaillon & M. Singer editors (1<sup>st</sup> ed.) Wiley VGH Verlag GmbH. 2018. pp 1583-1607.
126. **Opal SM**. “Innate immunity and the kidney”. In: Critical Care Nephrology (3rd ed.) Ronco, Bellomo, Kellum editors. Elsevier publishers, London, UK. 2018 chapter 82 pp. 476-482.
127. McCulloh RJ, **Opal SM**. “Sepsis management: Important Role of the pathogen.” In: Handbook of Sepsis (WJ Wiersinga and C. Seymour editors). Springer Nature Publishers. Chennai India 2018, Chapter 3, pp. 174-193
128. **Opal SM**, Pop-Vicas A. Molecular mechanisms of antibiotic resistance in bacteria. In: Principles and Practice of Infectious Diseases, 9th edition, JE Bennett, R Dolin and M Blaser (editors), 2018. Elsevier Publishers, Philadelphia, PA. (in press).
129. **Opal SM**. Introduction. A history of infectious diseases in human evolution. In Infectious Diseases: in Context. W. Powderly (editor) Elsevier Publishers, Philadelphia, PA. 2018 (in press).

Publications: 10/1/17 – 9/30/18

130. Kahler CW, Pantalone DW, Mastroleo NR, Liu T, Bove G, **Ramratnam B**, Monti PM, Mayer KH. Motivational interviewing with personalized feedback to reduce alcohol use in HIV-infected men who have sex with men: A randomized controlled trial. *J Consult Clin Psychol*. 2018 Aug;86(8):645-656. doi: 10.1037/ccp0000322. PMID: 30035581
131. Cheruiyot C, Pataki Z, **Ramratnam B**, Li M. Proteomic Analysis of Exosomes and Its Application in HIV-1 Infection. *Proteomics Clin Appl*. 2018 Apr 23:e1700142. doi: 10.1002/prca.201700142. [Epub ahead of print] Review. PMID: 29687643
132. Tang X, Lu H, Dooner M, Chapman S, Quesenberry PJ, **Ramratnam B**. Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes. *JCI Insight*. 2018 Apr 5;3(7). pii: 95676. doi: 10.1172/jci.insight.95676. [Epub ahead of print] PMID: 29618654
133. Moriarty K, Genberg B, Norman B, **Reece R**. The effect of antiretroviral stock-outs on medication adherence among patients living with HIV in Ghana: A Qualitative Study. (2018) *J Assoc Nurses AIDS Care*. Mar-Apr; 29(2):231-40. doi: 10.1016/j.jana.2017.09.014. PMID: 29239822
134. **Reece R**, Delong A, D'Antuono M, **Tashima K**, **Kantor R**. Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome. (2018) *J Clin Virol*. May 21; 105:11-7. PMID 29807234
135. Quilliam DN, LaPlante K, **Reece R**, Bandy U, Alexander-Scott N. Overview of Antimicrobial Stewardship Activities in Rhode Island. (2018) *R I Med J*. Jun 1; 101(5): 22-5. PMID: 29857600
136. **Reece R**, Chace P, Ranucci S. Antimicrobial Stewardship in Long-Term Care Facilities. (2018) *R I Med J*. June 1; 101(5): 42-4. PMID: 29857606
137. **Rice DP**, Ordoveza M, Palmer A, Wu G, Chirch LM. "Time to treatment initiation of direct acting antivirals for HIV/HCV coinfecting and HCV monoinfected patients." Accepted for publication by *AIDS Care* 7/10/2018.
138. Salazar JC, **Rice DP**. Neurosyphilis. In: *CNS Infections: A Clinical Approach*. García-Moncó JC, editor. London: Springer; 2018.
139. Guo Y, Tomich AD, McElheny CL, Cooper VS, Tait-Kamradt A, Wang M, Hu F, **Rice LB**, Sluis-Cremer N, Doi Y. High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium. *Emerg Infect Dis*. (11):1902-1904, November, 2017
140. Berganovic M, Luther MK, **Rice LB**, Arias CA, Rybak MJ, LaPlante KL. A review of combination antimicrobial therapy for enterococcus faecalis bloodstream infections and infective endocarditis. *Clin Infect Dis* (10) 1093, January 30, 2018

Publications: 10/1/17 – 9/30/18

141. **Rice LB**, Desbonnet C, Tait-Kamradt A, Garcia-Solache M, **Lonks J**, Moon TM, D'Andrea ED, Page R, Peti, W. Structural and regulatory changes in PBP4 trigger decreased  $\beta$ -lactam susceptibility in enterococcus faecalis. *MBio* 9(2) pil::e00361-18, April 3, 2018
142. Smith JM, Uvin AZ, Macmadu A, **Rich JD**. Epidemiology and Treatment of Hepatitis B in Prisoners. *Curr Hepatol Rep*. 2017 Sep;16(3):178-183. doi: 10.1007/s11901-017-0364-8. Epub 2017 Aug 7. PMID: 29450123
143. Green TC, **Rich JD**, Sharfstein J. Commentary on 'Revisiting the 'paradigm shift' in opioid use: Developments and implications 10 years later'. *Drug Alcohol Rev*. 2018 Apr;37 Suppl 1:S206-S207. doi: 10.1111/dar.12684. Epub 2018 Feb 26. No abstract available. PMID: 29479758
144. Brinkley-Rubinstein L, Macmadu A, Marshall BDL, Heise A, Ranapurwala SI, **Rich JD**, Green TC. Risk of fentanyl-involved overdose among those with past year incarceration: Findings from a recent outbreak in 2014 and 2015. *Drug Alcohol Depend*. 2018 Apr 1;185:189-191. doi: 10.1016/j.drugalcdep.2017.12.014. Epub 2018 Feb 9. PMID: 29459328
145. Montague BT, John B, Sammartino C, Costa M, Fukuda D, Solomon L, **Rich JD**. Use of viral load surveillance data to assess linkage to care for persons with HIV released from corrections. *PLoS One*. 2018 Feb 12;13(2):e0192074. doi: 10.1371/journal.pone.0192074. eCollection 2018. PMID: 29432472
146. Krieger MS, Yedinak JL, Buxton JA, Lysyshyn M, Bernstein E, **Rich JD**, Green TC, Hadland SE, Marshall BDL. High willingness to use rapid fentanyl test strips among young adults who use drugs. *Harm Reduct J*. 2018 Feb 8;15(1):7. doi: 10.1186/s12954-018-0213-2. PMID: 29422052
147. Ammon B, Iroh P, Tiruneh Y, Li X, Montague BT, **Rich JD**, Nijhawan AE. HIV Care After Jail: Low Rates of Engagement in a Vulnerable Population. *J Urban Health*. 2018 Mar 9. doi: 10.1007/s11524-018-0231-0. [Epub ahead of print] PMID: 29524033
148. Carroll JJ, **Rich JD**, Green TC. Reducing Collateral Damage in Responses to the Opioid Crisis. *Am J Public Health*. 2018 Mar;108(3):349-350. doi: 10.2105/AJPH.2017.304270. No abstract available. PMID: 29412724
149. Gordon MS, Crable EL, Carswell SB, Leopold J, Hodo-Powell J, McKenzie M, **Rich JD**. A Randomized Controlled Trial of Intensive Case Management (Project Bridge) for HIV-Infected Probationers and Parolees. *AIDS Behav*. 2018 Mar;22(3):1030-1038. doi: 10.1007/s10461-017-2016-y. PMID: 29273946
150. Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BDL, Alexander-Scott N, Boss R, **Rich JD**. Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. *JAMA Psychiatry*. 2018 Apr

- 1;75(4):405-407. doi: 10.1001/jamapsychiatry.2017.4614. No abstract available. PMID: 29450443
151. Claborn K, Becker S, Operario D, Safren S, **Rich JD**, Ramsey S. Adherence intervention for HIV-infected persons who use drugs: adaptation, open trial, and pilot randomized hybrid type 1 trial protocol. *Addict Sci Clin Pract*. 2018 Apr 2;13(1):12. doi: 10.1186/s13722-018-0113-5. PMID: 29606129
152. Costa M, Montague BT, Solomon L, Sammartino C, Gutman R, Zibman C, Rosen D, **Rich JD**. Assessing the Effect of Recent Incarceration in Prison on HIV Care Retention and Viral Suppression in Two States. *J Urban Health*. 2018 May 1. doi: 10.1007/s11524-018-0255-5. [Epub ahead of print] PMID: 29717402
153. Bernstein MH, Magill M, Beaudoin FL, Becker S, **Rich JD**. Harnessing the placebo effect: A promising method for curbing the opioid crisis? *Addiction*. 2018 Jul 10. doi: 10.1111/add.14385. [Epub ahead of print] No abstract available. PMID: 29989293
154. Brinkley-Rubinstein L, Sadacharan R, Macmadu A, **Rich JD**. Introduction to the Special Issue of the Journal of Urban Health on Incarceration and Health. *J Urban Health*. 2018 Jul 17. doi: 10.1007/s11524-018-0301-3. [Epub ahead of print] No abstract available. PMID: 30019116
155. Leader J, Bajwa A, Lanes A, Hua X, Rennicks White R, **Rybak N**, Walker M. The Effect of Very Advanced Maternal Age on Maternal and Neonatal Outcomes: A Systematic Review. *J Obstet Gynaecol Can*. 2018 Apr 19. pii: S1701-2163(17)30828-9. doi: 10.1016/j.jogc.2017.10.027. [Epub ahead of print] PMID: 29681506
156. Dethier D, **Rybak N**, Hirway P, Bachmaha M, Carroll J, Sorokolit A, **Flanigan T**, Sluzhynska M. The changing face of women living with HIV in western Ukraine. *Int J STD AIDS*. 2018 Mar;29(4):318-323. doi: 10.1177/0956462417724708. Epub 2017 Aug PMID: 28771077
157. Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Tepler H; ONCEMRK Study Group. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. **Tashima KT**, 1 of 140 Collaborators. *Lancet HIV*. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11. PMID: 28918877
158. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a



- randomised, double-blind, phase 3, non-inferiority trial. **Tashima KT**, 1 of 125 Collaborators. *Lancet HIV*. 2018 Mar 23. pii: S2352-3018(18)30021-3. doi: 10.1016/S2352-3018(18)30021-3. [Epub ahead of print] PMID: 29592840
159. **Tunkel AR**, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, van de Beek D, Bleck TP, Garton HJL, Zunt JR. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. *Clin Infect Dis* 2017;64:e34-e65. DOI: 10.1093/cid/ciw861.
160. Mangione S, Chakraborti C, Staltari G, Harrison R, **Tunkel AR**, Liou KT, Cerceo E, Voeller M, Bedwell WL, Fletcher K, Kahn MJ. Medical students' exposure to the humanities correlates with positive personal qualities and reduced burnout: A multi-institutional US survey. *J Gen Intern Med* 2018; DOI: 10.1007/s11606-017-4275-8.
161. Monteiro KA, Dietrich K, Borkan J, **Tunkel AR**, Dollase R, George P. Use of validated questionnaires to assess baseline characteristics of incoming medical students enrolled in a unique Primary Care-Population Medicine Program. *Family Med* 2018;50:372-375.
162. Borkan J, George P, **Tunkel AR**. Curricular transformation: the case against global change. *Acad Med* 2018; DOI: 10.1097/ACM.0000000000002147.
163. **Tunkel AR**. Pathogenesis and pathophysiology of bacterial meningitis. In: *UpToDate*. Basow DS, ed. Waltham, MA. 2018.
164. **Tunkel AR**. Clinical features and diagnosis of acute bacterial meningitis in adults. In: *UpToDate*. Basow DS, ed. Waltham, MA. 2018.
165. Hasbun R, **Tunkel AR**. Approach to the patient with central nervous system infection. In: Principles and Practice of Infectious Diseases, 9<sup>th</sup> ed. Bennett JE Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. In press.
166. Hasbun R, van de Beek D, Brouwer MC, **Tunkel AR**. Acute meningitis. In: Principles and Practice of Infectious Diseases, 9<sup>th</sup> ed. Bennett JE Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. In press.
167. Gea-Banacloche JC, **Tunkel AR**. Brain abscess. In: Principles and Practice of Infectious Diseases, 9<sup>th</sup> ed. Bennett JE, Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. In press.
168. **Tunkel AR**. Subdural empyema, epidural abscess, and suppurative intracranial thrombophlebitis. In: Principles and Practice of Infectious Diseases, 9<sup>th</sup> ed. Bennett JE, Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. In press.
169. Bhimraj A, **Tunkel AR**. Cerebrospinal fluid shunt and drain infections. In: Principles and Practice of Infectious Diseases, 9<sup>th</sup> ed. Bennett JE, Dolin R, Blaser MJ, eds. Philadelphia: Elsevier Saunders. In press.

Publications: 10/1/17 – 9/30/18

170. Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, van de Beek D, Bleck TP, Zunt JR, **Tunkel AR**. Reply to Kuehl et al. Digging out the evidence – how strong is the IDSA recommendation against antibiotic prophylaxis in basilar skull fracture and cerebrospinal fluid leakage? *Clin Infect Dis* 2018;66:1320-1321.
171. Weiss A, Rich J, **Wing EJ**. Posterior reversible encephalopathy syndrome in a patient with HIV/AIDS and immune reconstitution syndrome: a case study and literature review. Oxford Medical Case Reports (accepted for publication).
172. **Wing, EJ**. Chapter “HIV and Aging—a multifaceted relationship.” In Ahmad S (ed), *Aging: Exploring a Complex Phenomenon*. CRC Press: Boca Raton, 2018, pp. 259–270.